Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients
Brief Summary: The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.


Options:
A: Arm Label: CNTO 1959 (5 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (5 mg) | Arm Label: CNTO 1959 (15 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (15 mg) | Arm Label: CNTO 1959 (50 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (50 mg) | Arm Label: CNTO 1959 (100 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (100 mg) | Arm Label: CNTO 1959 (200 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (200 mg) | Arm Label: Adalimumab (approved psoriasis dosing); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Arm Label: Placebo to CNTO 1959 (100 mg); Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1959 (100 mg), Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1959 (5 mg); Assigned to Arm(s): CNTO 1959 (5 mg) | Intervention Type: DRUG; Name: CNTO 1959 (15 mg); Assigned to Arm(s): CNTO 1959 (15 mg) | Intervention Type: DRUG; Name: CNTO 1959 (50 mg); Assigned to Arm(s): CNTO 1959 (50 mg) | Intervention Type: DRUG; Name: CNTO 1959 (100 mg); Assigned to Arm(s): CNTO 1959 (100 mg), Placebo to CNTO 1959 (100 mg) | Intervention Type: DRUG; Name: CNTO 1959 (200 mg); Assigned to Arm(s): CNTO 1959 (200 mg) | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab (approved psoriasis dosing) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo to CNTO 1959 (100 mg)
B: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo
C: Arm Label: Placebo Comparator: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Voclosporin 0.2 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.3 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.4 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Intervention Type: DRUG; Name: voclosporin; Assigned to Arm(s): Voclosporin 0.2 mg/kg po BID, Voclosporin 0.3 mg/kg po BID, Voclosporin 0.4 mg/kg po BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 1
D: Arm Label: Cohort A: INCB018424 Ruxolitinib 0.5%; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib phosphate cream, Drug: Placebo cream | Arm Label: Cohort B: INCB018424 Ruxolitinib 1.0%; Type: EXPERIMENTAL; Interventions: Drug: Placebo cream, Drug: Ruxolitinib phosphate cream | Arm Label: Cohort C: INCB018424 Ruxolitinib 1.5%; Type: EXPERIMENTAL; Interventions: Drug: Placebo cream, Drug: Ruxolitinib phosphate cream | Arm Label: Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene; Type: EXPERIMENTAL; Interventions: Drug: Dovonex® calcipotriene 0.005% | Arm Label: Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate; Type: EXPERIMENTAL; Interventions: Drug: Diprolene® AF betamethasone dipropionate 0.05% cream. | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort A: INCB018424 Ruxolitinib 0.5% | Intervention Type: DRUG; Name: Dovonex® calcipotriene 0.005%; Assigned to Arm(s): Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene | Intervention Type: DRUG; Name: Diprolene® AF betamethasone dipropionate 0.05% cream.; Assigned to Arm(s): Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate | Intervention Type: DRUG; Name: Placebo cream; Assigned to Arm(s): Cohort A: INCB018424 Ruxolitinib 0.5%, Cohort B: INCB018424 Ruxolitinib 1.0%, Cohort C: INCB018424 Ruxolitinib 1.5% | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort B: INCB018424 Ruxolitinib 1.0% | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort C: INCB018424 Ruxolitinib 1.5%

Answer: C